𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Combined effects of adeno-associated virus vector and a herpes simplex virus mutant as neoplastic therapy

✍ Scribed by Hideki Kasuya; Masaaki Mizuno; Jun Yoshida; Yukihiro Nishiyama; Shuji Nomoto; Akimasa Nakao

Publisher
John Wiley and Sons
Year
2000
Tongue
English
Weight
741 KB
Volume
74
Category
Article
ISSN
0022-4790

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Combinatorial engineering of a gene ther
Combinatorial engineering of a gene therapy vector: directed evolution of adeno-associated virus
✍ Luca Perabo; Jan Endell; Susan King; Kerstin Lux; Daniela Goldnau; Michael Halle πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 255 KB

## Abstract ## Background Viruses are being exploited as vectors to deliver therapeutic genetic information into target cells. The success of this approach will depend on the ability to overcome current limitations, especially in terms of safety and efficiency, through molecular engineering of the

Identification of a replication-defectiv
Identification of a replication-defective herpes simplex virus for recombinant adeno-associated virus type 2 (rAAV2) particle assembly using stable producer cell lines
✍ Estelle Toublanc; Abdellatif Benraiss; Delphine Bonnin; VΓ©ronique Blouin; Nicole πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 387 KB

## Abstract ## Background The development of stable producer cell lines for recombinant adeno‐associated virus (rAAV) assembly is a strategy followed by many groups to develop scalable production methods suitable for good manufacturing practice (GMP) requirements. The major drawback of this method

Potential for combined therapy with 348u
Potential for combined therapy with 348u87, a ribonucleotide reductase inhibitor, and acyclovir as treatment for acyclovir-resistant herpes simplex virus infection
✍ Dr. S. Safrin; T. Schacker; J. Delehanty; E. Hill; L. Corey πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 348 KB

inhibitors of the ribonucleotide reductase of herpes simplex viruses (HSV) potentiate the activity of acyclovir in vitro and in animal studies. In addition, the combination of the ribonucleotide reductase inhibitor 348U87 and acyclovir has synergistic therapeutic effects against infections in mice d